Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.74 |
| ▸ | GSK3B | P49841 | 3/20 | 0.60 |
| ▸ | BACE1 | P56817 | 3/20 | 0.60 |
| ▸ | PPARG | P37231 | 3/20 | 0.59 |
| ▸ | PPARA | Q07869 | 2/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | PPARD | Q03181 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.55 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308482 | 1.00 | LCK (0.77) | LCKCYP1A2CYP1A1CYP19A1GSK3B | |
| SCHEMBL3650797 | 1.00 | LCK (0.77) | LCKCYP1A2CYP1A1CYP19A1GSK3B | |
| SCHEMBL6796518 | 0.95 | LCK (0.74) | LCKCYP1A2CYP1A1CYP19A1GSK3B | |
| SCHEMBL28441803 | 0.93 | CYP1A2 (0.73) | LCKCYP1A2CYP1A1CYP19A1GSK3B | |
| SCHEMBL20024692 | 0.91 | LCK (0.77) | LCKCYP1A2CYP1A1CYP19A1GSK3B | |
| SCHEMBL14786203 | 0.91 | LCK (0.77) | LCKCYP1A2CYP1A1CYP19A1GSK3B | |
| SCHEMBL1975680 | 0.91 | LCK (0.68) | LCKCYP1A2CYP1A1CYP19A1PPARG | |
| SCHEMBL1975681 | 0.91 | LCK (0.68) | LCKCYP1A2CYP1A1CYP19A1PPARG | |
| SCHEMBL8913578 | 0.89 | LCK (0.81) | LCKCYP1A2CYP1A1CYP19A1GSK3B | |
| SCHEMBL8913590 | 0.89 | LCK (0.81) | LCKCYP1A2CYP1A1CYP19A1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1466884-A1 | Process for the preparation of resveratrol and its uses | Sochinaz SA (CH) | 2004-10-13 | — | — | EP | claimed |
| WO-2001060774-A1 | SYNTHESIS OF RESVERATROL | BRIGHAM YOUNG UNIVERSITY (US) | 2001-08-23 | — | — | WO | claimed |
| CN-106336347-B | New method for synthesizing hydroxystilbenes | 中国科学院成都有机化学有限公司 | 2020-08-18 | — | — | CN | disclosed |
| US-20170362152-A1 | NOVEL 1,2-DIPHENYLETHYLENE GLYCOL COMPOUNDS FOR COMBATING AGING OF THE SKIN, AND COSMETIC USE THEREOF | L'OREAL (FR) | 2017-12-21 | — | — | US | disclosed |
| EP-2205544-B1 | PROCESS FOR THE SYNTHESIS OF POLYHYDROXYSTILBENE COMPOUNDS | CLARIANT SPECIALTY FINE CHEM F (FR) | 2013-11-06 | — | — | EP | disclosed |
| US-8399714-B2 | Process for the synthesis of polyhydroxystilbene compounds | CLARIANT SPECIALITY FINE CHEMICALS (FRANCE) (FR) | 2013-03-19 | — | — | US | disclosed |
| US-20100324342-A1 | PROCESS FOR THE SYNTHESIS OF POLYHYDROXYSTILBENE COMPOUNDS | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2010-12-23 | — | — | US | disclosed |
| EP-2205544-A1 | PROCESS FOR THE SYNTHESIS OF POLYHYDROXYSTILBENE COMPOUNDS | Clariant Specialty Fine Chemicals (France) (FR) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009043761-A1 | PROCESS FOR THE SYNTHESIS OF POLYHYDROXYSTILBENE COMPOUNDS | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2009-04-09 | — | — | WO | disclosed |
| US-6844471-B2 | Method for the conversion of a Z-isomer into E-isomer | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2005-01-18 | — | — | US | disclosed |
| EP-1466884-A1 | Process for the preparation of resveratrol and its uses | Sochinaz SA (CH) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004009539-A2 | METHOD FOR THE CONVERSION OF A Z-ISOMER INTO E-ISOMER | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2004-01-29 | — | — | WO | disclosed |
| US-20040015020-A1 | Method for the conversion of a Z-isomer into E-isomer | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2004-01-22 | — | — | US | disclosed |
| WO-2003094833-A2 | A NEW STEREOSELECTIVE ROUTE TO PRODUCE TRIS-O-SUBSTITUTED-(E)-( 3,5-DIHYDROXYPHENYL)-2-(4- HYDROXYPHENYL)ETHENE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-11-20 | — | — | WO | disclosed |
| US-6552213-B1 | Oxidation and halogenation of such as 3,4',5-tribenzyloxy-dibenzylsulfide; reductive dehalogenation desulfonation; hydrolysis | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED, INDIA (IN) | 2003-04-22 | — | — | US | disclosed |
| WO-2001060774-A1 | SYNTHESIS OF RESVERATROL | BRIGHAM YOUNG UNIVERSITY (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040015020-A1 | Method for the conversion of a Z-isomer into E-isomer | ECH1, CYP1A1, KEAP1 | LCK 4680/4885CYP1A2 106/4885CYP1A1 2/4885 |
| US-20100324342-A1 | PROCESS FOR THE SYNTHESIS OF POLYHYDROXYSTILBENE COMPOUNDS | ASH2L, ASPH, HRH1 | LCK 2457/4885CYP1A2 200/4885CYP1A1 91/4885 |
| US-20170362152-A1 | NOVEL 1,2-DIPHENYLETHYLENE GLYCOL COMPOUNDS FOR COMBATING AGING OF THE SKIN, AND COSMETIC USE THEREOF | GLA, DSG1, GPX1 | LCK 3536/4885CYP1A2 1230/4885CYP1A1 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.